IMedis

Company Overview

Snapshot

Founded in January 2018 by Aviel Blumenfeld and Yitzi Pfeffer, IMedis operates with over 1,000 employees. The company has secured funding across three rounds from two investors, with Sanara Ventures leading one of its pre-seed rounds. IMedis received CE approval for its radiology scans in the EU in January 2021.

Business overview

IMedis develops an AI-driven cloud-based quality management system for radiology departments. The company's core technology aggregates and analyzes data from PACS and RIS to identify failure points within the radiology workflow. This solution aims to reduce risk, improve financial efficacy, and generate new business opportunities for healthcare providers. Its first commercially available module, Duali-Q, focuses on managing and following up on errors of omission in CT scans of the chest and abdomen, serving teaching hospitals in the United States, United Kingdom, and Israel.

Strategic signal

In January 2021, IMedis received CE approval for its radiology scans in the EU. This regulatory milestone is a significant validation of the company's technology and opens up access to the European market, signaling strong potential for international expansion and increased adoption of its AI-powered diagnostic solutions within the digital healthcare sector.

Company Intelligence Q&A

When was IMedis founded?

IMedis was founded in January 2018 by Aviel Blumenfeld and Yitzi Pfeffer.

What is IMedis's primary product?

IMedis's primary product is Duali-Q, an AI-powered module designed for the management and follow-up of errors of omission in CT scans of the chest and abdomen.

Which investor led a funding round for IMedis?

Sanara Ventures led a pre-seed funding round for IMedis in April 2018.

What significant regulatory approval did IMedis receive?

In January 2021, IMedis received CE approval for its radiology scans in the EU, enabling its technology to be used in European markets.

What was a key finding from a study involving Duali-Q?

A recent study demonstrated that Duali-Q increased detection rates of life-threatening diseases by 13%.